ArticleCEN case reports2025
Tubular damage and SGLT2 expression in a patient with Beni-koji tablet-associated acute kidney injury and Fanconi syndrome.
Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Red yeast rice supplement containing silica nanoparticles induces renal injury in rats with unilateral nephrectomy.Clinical and experimental nephrology · 2026Article
- One-Year Follow-Up of Red Yeast Rice-Associated Renal Dysfunction: A Report of Two Cases.Cureus · 2026Article
- Two Cases of Chronic Tubular Necrosis Presenting as Fanconi Syndrome Induced by Red Yeast Rice Choleste-Help.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since March 2024, many cases of renal dysfunction have been reported in Japan among individuals taking a supplement containing red yeast rice. We present the case of a 51-year-old woman who developed renal dysfunction and Fanconi syndrome after taking the supplement. The patient was referred to our hospital with hypouricemia, hypokalemia, hypophosphatemia, and glucosuria. Following a renal biopsy broadcast reports of kidney damage caused by the red yeast rice supplement and the patient's declaration of taking this supplement, we diagnosed her with supplement-induced acute kidney injury and Fanconi syndrome. Renal pathological findings revealed acute tubular necrosis, including brush border loss and mitochondrial fragmentation in the proximal tubular cells. These were consistent with the clinical and pathological findings of previous cases involving the red yeast rice supplement. Additionally, a reduction in sodium-glucose co-transporter 2 (SGLT2) expression was observed in the proximal tubules, supporting that the red yeast rice supplement damaged the proximal tubular cells. The reduction of SGLT2 protein expression may be linked to supplement-induced glucosuria. After supplement intake was ceased, renal function recovered and laboratory findings including glucosuria returned to normal within 6 months. The loss of glucosuria suggests that SGLT2 protein expression may be reversible. In consideration of our case and previous cases, it is probable that the nephrotoxicity of red yeast rice supplement is primarily affecting the proximal tubules, particularly the S1 and S2 segments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.